Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.The agent also appeared associated with fewer treatment-related adverse events.“Pembrolizumab should be considered a new standard of care for these patients,” Thierry André, MD, professor of medical oncology at University Sorbonne and head of the medical oncology department at Hôpital Saint Antoine in Paris, said during aRead More

Share on facebook
Share on twitter
Share on linkedin